Monopar Therapeutics Inc. Retained Earnings
Monopar Therapeutics Inc. (MNPR) had Retained Earnings of -$98.72 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$98.72M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$93.40M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$89.51M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$84.31M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$98.72M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$93.40M 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$89.51M 10-Q · filed 2026-08-12 |
| 2025-09-30 | -$84.31M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$80.87M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$78.42M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$75.79M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$64.87M 10-Q · filed 2024-11-08 |
| 2024-06-30 | -$63.56M 10-Q · filed 2024-08-09 |
| 2024-03-31 | -$61.85M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$60.21M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$58.39M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$56.44M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$54.24M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$51.80M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$48.91M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$46.51M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$43.75M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$41.29M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$38.61M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$36.15M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$34.07M 10-Q · filed 2021-05-13 |
| 2020-12-31 | -$32.19M 10-K · filed 2022-03-24 |
| 2020-09-30 | -$30.06M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$28.42M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$26.97M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$25.88M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$24.67M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$3.46K 10-Q · filed 2019-08-08 |
| 2019-03-31 | -$23.03M 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$21.66M 10-K · filed 2020-03-27 |
| 2018-09-30 | -$20.77M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$20.13M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$19.30M 10-Q · filed 2018-05-11 |
| 2017-12-31 | -$18.43M 10-K · filed 2019-02-26 |
| 2016-12-31 | -$1.87M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |